section name header

Information

Editors

FredrikÅberg

Gilbert's Syndrome

Essentials

  • This benign disorder presenting as asymptomatic jaundice should be identified in order to avoid unnecessary extensive examinations and referrals to hospital.

Epidemiology

  • The prevalence in Caucasian populations is about 2-12%.
  • It is 3 times more common in men than in women.

Aetiology and findings

  • Gilbert's syndrome is a group of inherited disorders of bilirubin metabolism with an autosomal inheritance pattern essentially characterized by an increase in serum unconjugated bilirubin and intermittent jaundice.
  • The disorder is caused by defective conjugation of bilirubin in the liver due to a UGT1A1 gene mutation and consequently decreased clearance of bilirubin without other signs of liver failure or haemolysis.
  • The condition is a benign normal variant not causing any other symptoms apart from jaundice.
  • Jaundice is usually first observed at the age of 15-30 years, typically in association with some transient condition raising bilirubin levels (such as fasting, physical exertion, infection or alcohol consumption).
  • Some variants are inherited as an autosomal dominant trait, in which case Gilbert's syndrome occurs in several family members.

Diagnosis

  • The diagnosis can be made in primary health care if all of the following criteria are fulfilled:
    • clinical jaundice or randomly increased bilirubin concentration (usually below 70 µmol/l)
    • conjugated bilirubin normal or below 30% of total bilirubin
    • other liver values normal (ALT, AST, ALP, GT)
    • haemolysis tests normal (Hb, reticulocytes, haptoglobin).
  • In unclear cases, blood tests should be repeated once after 6-12 months.
  • Upper abdominal ultrasonography is indicated only if other liver disease is suspected.
  • Liver biopsy is not necessary.

Differential diagnosis

Treatment

  • The disorder is benign. There is no need for treatment, advice on lifestyle or follow-up.
  • Most drugs with elimination depending on bilirubin conjugation can be used for patients with Gilbert's syndrome but the reduced UGT1A1 activity associated with the syndrome is significant for some rarely used types of medication (such as irinotecan or atazanavir).
  • It has been suggested that antioxidative effects of bilirubin and its effect on intracellular signalling pathways may protect patients with Gilbert's syndrome against cardiovascular disease, certain types of cancer and autoimmune diseases, but the syndrome may also be associated with an increased risk of gallstones.

    References

    • Vítek L, Tiribelli C. Gilbert's syndrome revisited. J Hepatol 2023;79(4):1049-1055. [PubMed]

Related Keywords

ATC Code:

Primary/Secondary Keywords